Optimizing Dermatology Availity Integration for Prior Authorization Workflows

Effective dermatology Availity integration is critical for managing the high volume of prior authorizations required for biologics, specialty drugs, and procedures like Mohs surgery. Klivira streamlines this workflow, connecting your EMR to Availity's multi-payer network.

Revenue cycle directors and prior authorization coordinators in dermatology practices face unique challenges, from complex step therapy requirements for biologics to varying payer policies for Mohs surgery. Manual submissions via Availity Essentials consume significant staff time and are prone to errors. Automating this process through a robust Availity integration can significantly reduce administrative burden and accelerate patient access to critical treatments.

The Challenge of Dermatology Prior Authorizations

Dermatology practices frequently encounter prior authorization requirements for high-cost biologics such as Dupixent, Cosentyx, Tremfya, Skyrizi, and Humira, used for conditions like psoriasis, atopic dermatitis, and hidradenitis suppurativa. Additionally, Mohs micrographic surgery, a common procedure for non-melanoma skin cancers, often triggers PA. These authorizations demand precise documentation, adherence to clinical guidelines like AAD and NCCN, and often involve periodic re-authorizations for chronic treatments.

Key PA Triggers in Dermatology Requiring Availity Submission

Biologics for psoriasis and psoriatic arthritis (e.g., TNF inhibitors, IL-17/23 inhibitors)
Biologics for atopic dermatitis (e.g., dupilumab, tralokinumab, JAK inhibitors)
Hidradenitis suppurativa biologics (e.g., adalimumab, secukinumab)
Mohs micrographic surgery for cosmetically sensitive areas
Advanced skin cancer treatments (e.g., immunotherapy for melanoma)
Home phototherapy for psoriasis and other conditions

Leveraging Availity for Dermatology PA Submissions

Availity, as a prominent multi-payer clearinghouse, serves as a primary channel for submitting prior authorization requests to numerous commercial payers. For dermatology, this means navigating diverse payer policies for biologics and procedures through a standardized portal. Klivira's integration with Availity facilitates electronic submission of X12 278 transactions, ensuring that detailed clinical documentation, often pulled directly from the EMR, reaches the payer efficiently and accurately.

Addressing Common Dermatology PA Denials via Integration

Many dermatology PA denials stem from insufficient documentation regarding step therapy compliance, disease severity scores (PASI, EASI, BSA), or lack of pre-biologic screenings (TB, hepatitis). For Mohs surgery, denials often relate to non-conformance with AAD Appropriate Use Criteria. An integrated solution can flag these requirements proactively, ensuring that all necessary data, aligned with AAD Clinical Guidelines and NCCN frameworks, is included in the initial Availity submission, thereby reducing the likelihood of denials.

Klivira's Approach to Dermatology Availity Integration

Klivira connects your EMR to Availity, automating the extraction of relevant clinical data for dermatology prior authorizations. Our platform applies AAD-guideline-aware step-therapy logic for biologics and AUC validation for Mohs surgery, ensuring submissions meet payer criteria. We manage periodic re-authorization workflows for chronic biologic treatments and intelligently route requests based on medical-vs-pharmacy benefit distinctions, optimizing efficiency and compliance.

Frequently asked questions

How does Klivira handle the specific documentation requirements for dermatology biologics when integrating with Availity?

Klivira's platform is designed to extract specific clinical data points from your EMR, such as PASI/BSA scores for psoriasis, EASI/SCORAD for atopic dermatitis, and documentation of prior topical or systemic therapy trials, as required by AAD Clinical Guidelines. This data is then structured for electronic submission via Availity, ensuring comprehensive and compliant requests.

Can Klivira's Availity integration support Mohs surgery prior authorizations?

Yes, our integration specifically addresses Mohs micrographic surgery. The system validates submissions against AAD Appropriate Use Criteria, ensuring that tumor type, site, and other relevant factors are accurately documented and submitted through Availity, reducing denials related to AUC mismatches.

How does the integration manage re-authorizations for chronic dermatology conditions?

For chronic conditions requiring biologics, such as psoriasis or atopic dermatitis, Klivira automates the tracking and initiation of periodic re-authorization cycles (e.g., every 6 or 12 months). The system can pre-populate re-authorization requests with updated clinical information from your EMR and submit them via Availity, minimizing administrative overhead.

What EMR touchpoints are involved in a dermatology Availity integration?

The integration typically involves pulling patient demographics, diagnosis codes, procedure codes, medication lists, clinical notes detailing disease severity and prior treatment trials, and lab results (e.g., TB/hepatitis screenings) directly from your EMR. This data is then mapped and transmitted to Availity using standard electronic prior authorization (ePA) protocols like X12 278.

Does Klivira's integration help differentiate between medical and pharmacy benefit PAs for dermatology drugs?

Yes, our platform intelligently routes prior authorization requests based on whether the drug falls under the medical or pharmacy benefit. This is crucial for dermatology, where biologics can be self-injected (pharmacy benefit) or administered in a clinic (medical benefit), ensuring the correct submission channel is utilized through Availity.